ロード中...
Examination of Diagnostic Accuracy of UroVysion Fluorescence In Situ Hybridization for Bladder Cancer in a Single Community of Japanese Hospital Patients
OBJECTIVE: UroVysion (Abbott Molecular, Inc., Illinois, USA) is based on multicolor fluorescence in situ hybridization (FISH). It has been used successfully in the USA following its Food and Drug Administration approval in 2001. However, the technology was not approved for use in Japan until 2017. C...
保存先:
| 出版年: | Asian Pac J Cancer Prev |
|---|---|
| 主要な著者: | , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
West Asia Organization for Cancer Prevention
2019
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6948889/ https://ncbi.nlm.nih.gov/pubmed/31030505 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.31557/APJCP.2019.20.4.1271 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|